This module summarises key recommendations and statements of the EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease published in 2024.
Welcome to this EASD e-Learning Module on the management of MASLD, which is short for metabolic dysfunction-associated steatotic liver disease, previously termed NAFLD. This module focuses on the EASL-EASD-EASO Clinical Practice Guidelines, which were published online in June 2024. My name is Michael Roden. I'm internist, endocrinologist and diabetologist at the German Diabetes Centre in the University Hospital Dusseldorf in Germany, and I served already 2016 and again for the 2024 Guidelines as a co-chair of the Clinical Practice Guideline Panel. My name is Amalia Gastaldelli. I am a Research Director of the Institute of Clinical Physiology of the National Research Council in Pisa, Italy, where I lead a group that studies the cardiometabolic risk and I have been studying the pathophysiology of MASLD for the last 25 years. I served as a member of the Clinical Practice Guideline Panel as a delegate of the EASD. Topics we will cover together in this EASD e-Learning module are the background, the epidemiology, rationale, diagnostics and definition, as well as the medical, the drug treatment, surgical treatment, and finally, the specific aspects of the complicated and progressive liver disease, cirrhosis and hepatocellular carcinoma. I will guide you through the chapters that will investigate the diagnostic tools, 32 the case findings and risk assessment, and also the general consideration, the non-pharmacological therapy for MASLD.Video transcript
By the end of this module, you will be able to:
✓ Understand the rationale and the clinical implications of the recently introduced nomenclature of metabolic dysfunction-associated steatotic liver disease (MASLD), as compared to the former term non-alcoholic fatty liver disease (NAFLD).
✓ Recognise the diagnostic algorithm for MASLD and metabolic dysfunction-associated steatohepatitis (MASH) as well as the proposed strategy to assess the risk of advanced fibrosis and other liver-related outcomes.
✓ Interpret current evidence and guideline recommendations to guide the selection of non-pharmacological, pharmacological, and interventional (surgical) therapies for the prevention and treatment of MASLD and its complications and comorbidities.
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.